Lakefront Biotherapeutics (LKFT) Inventory Average (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Inventory Average for 9 consecutive years, with $22.9 million the latest figure, recorded in Q1 2026.

• Quarterly Inventory Average fell 55.2% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.9 million (down 55.2% YoY) and the FY2025 annual result came in at $41.9 million, down 41.13% from the prior year.
• Inventory Average fell to $22.9 million in Q1 2026 per LKFT's latest filing, from $25.9 million in the prior quarter.
• Over the last five years, Inventory Average for LKFT reached as high as $87.9 million in Q1 2024 and fell as low as $22.2 million in Q1 2022.
• A 5-year average of $48.3 million and a median of $46.1 million in 2025 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2023 — Inventory Average surged 168.68% — and 2025, when it slumped 61.08%.
• Year by year, Inventory Average stood at $22.2 million in 2022, then surged by 232.55% to $73.7 million in 2023, then fell by 9.9% to $66.4 million in 2024, then sank by 61.08% to $25.9 million in 2025, then dropped by 11.56% to $22.9 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $22.9 million, $25.9 million, and $32.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.